Page last updated: 2024-08-23

acetylshikonin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

acetylshikonin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bai, S; Fan, C; Hao, G; Jiang, H; Qiu, Y; Sun, L; Wu, M; Yang, Z; Yu, L; Zhai, J; Zhang, Y1

Other Studies

1 other study(ies) available for acetylshikonin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 122

    Topics: Animals; Anthraquinones; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line; Cell Proliferation; Chlorocebus aethiops; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Signal Transduction; Vero Cells

2020